Literature DB >> 2910253

Cachectin activity in the serum of cachectic, tumor-bearing rats.

M C Stovroff1, D L Fraker, J A Norton.   

Abstract

Cachectin/tumor necrosis factor has been postulated to be a possible mediator of cancer cachexia. Using a sensitive bioassay, we attempted to detect circulating cachectin activity in the serum of sarcoma-bearing rats and to correlate levels with measurements of cachexia and the extent of disease. In addition, we resected the tumor to determine the time course of reversal of cachexia and the disappearance of cachectin activity in the serum. Circulating cachectin activity was not detectable in the serum of non-tumor-bearing rats or in tumor-bearing rats until 28 days after implantation. With evidence of food intake and body weight decline, cachectin activity became detectable in the serum and levels increased as cachexia and tumor burden increased. Serum cachectin activity levels correlated directly with tumor burden and inversely with food intake and body weight change. After resection of the tumor, food intake and body weight increased and serum cachectin activity became undetectable. Serum triglyceride levels were higher in cachectic tumor-bearing rats than in pair-fed non-tumor-bearing controls, and levels decreased after tumor resection as cachectin activity decreased. The results suggest that cachectin is a humoral mediator of cachexia in this rat-tumor model.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2910253     DOI: 10.1001/archsurg.1989.01410010104021

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  16 in total

1.  Protein turnover, synthesis and secretion of albumin in hepatocytes isolated from rats bearing Walker 256 carcinoma.

Authors:  P Villa; P Arioli; A Guaitani
Journal:  In Vitro Cell Dev Biol       Date:  1992-03

Review 2.  Metabolic alteration in patients with cancer: nutritional implications.

Authors:  Y Sakurai; S Klein
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

3.  Role of insulin resistance in decreasing lipoprotein lipase activity in tumor-bearing rats.

Authors:  Y Noguchi; K Nomura; T Yoshikawa; K Fukuzawa; T Makino; A Tsuburaya; A Matsumoto
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

Review 4.  Cancer cachexia.

Authors:  M J Tisdale; S A Beck
Journal:  Int J Pancreatol       Date:  1990 Aug-Nov

5.  Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia.

Authors:  K J Tracey; S Morgello; B Koplin; T J Fahey; J Fox; A Aledo; K R Manogue; A Cerami
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

Review 6.  Are cytokines possible mediators of cancer cachexia?

Authors:  Y Noguchi; T Yoshikawa; A Matsumoto; G Svaninger; J Gelin
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

7.  A sarcoma-derived protein regulates hepatocyte metabolism via autocrine production of tumor necrosis factor-alpha.

Authors:  C P Fischer; B P Bode; W W Souba
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

Review 8.  Glutamine and cancer.

Authors:  W W Souba
Journal:  Ann Surg       Date:  1993-12       Impact factor: 12.969

9.  Decrease of glutaminase expression by interferon-gamma in human intestinal epithelial cells.

Authors:  P Sarantos; Z Abouhamze; E M Copeland; W W Souba
Journal:  Ann Surg Oncol       Date:  1994-09       Impact factor: 5.344

10.  Elevated circulating interleukin-6 is associated with an acute-phase response but reduced fixed hepatic protein synthesis in patients with cancer.

Authors:  K C Fearon; D C McMillan; T Preston; F P Winstanley; A M Cruickshank; A Shenkin
Journal:  Ann Surg       Date:  1991-01       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.